Lorlatinib price in Bangladesh (2026)

There is no fixed public retail price for lorlatinib in Bangladesh in the sources we track (most supply is hospital- or named-patient based). Use the Bangladesh list price as the benchmark: BDT 1,660–BDT 1,660 (US$13.51–US$13.51) per unit, about BDT 1,660–BDT 1,660 in BDT per unit and BDT 49,800–BDT 49,800 per 30-unit month, before freight, customs duty and distributor margin.

Yes, but only through the rules of the Directorate General of Drug Administration (DGDA): Bangladesh is the reference market for this price guide: it is a least-developed-country WTO member with a patent exemption for pharmaceuticals until 2033, so local manufacturers legally produce on-patent molecules. Products are registered with the DGDA and carry a Bangladesh MRP; buying at pharmacy level usually means a per-strip or per-box price in BDT. Prescription medicines must move on a valid prescription through a licensed importer, pharmacy or hospital; personal-use imports need a named-patient / compassionate-use authorisation.

We cannot confirm the registration status of every individual generic brand in Bangladesh. Directorate General of Drug Administration (DGDA) is the approving authority, and only products with a local product registration (or a special import authorisation) may be sold routinely. Ask your supplier for the local registration or import permit for the specific brand before you buy.

Bangladesh is a least-developed-country WTO member with a pharmaceutical patent exemption running to 2033, so local manufacturers can legally produce molecules that are still on patent elsewhere — and DGDA-registered list prices are public. That makes it the practical global floor price for on-patent targeted therapy and the benchmark used in import negotiations.

Bangladesh: Local brands marketed. Beacon (Loranix) and Everest (Lorbrexen) lorlatinib tablets are listed in the national MedEx drug index; originator Lorbrena availability in Bangladesh not confirmed.